Anonymous
Guest
Anonymous
Guest
Often, the terms of the contract between the CSO and the client pharma company will measure the number of vacant territories and number of details per call cycle as part of the determination of the compensation due to the CSO.
So, interviewing and even filling vacant territories even though the contract is not yet extended helps the CSO to meet THEIR metrics with their client. At the very least, it makes sure the pipeline is full of candidates to fill vacancies once the extension decision is made.
Unfortunately, it has little to do with the likelihood of an extension. I'd be very hesitant to take a position on Oceans at this point.
So, interviewing and even filling vacant territories even though the contract is not yet extended helps the CSO to meet THEIR metrics with their client. At the very least, it makes sure the pipeline is full of candidates to fill vacancies once the extension decision is made.
Unfortunately, it has little to do with the likelihood of an extension. I'd be very hesitant to take a position on Oceans at this point.